First Commercial Imaging Lab to Offer Quantitative Coronary Angiographic
Analysis With Integrated eCRF
DUBLIN, August 11 /PRNewswire-FirstCall/ -- ICON plc (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that its Medical Imaging division has become the first commercial imaging core laboratory to offer Quantitative Coronary Angiographic (QCA) analysis with an integrated electronic Case Report Form (eCRF).
This new service has been made possible through the integration of QCAPlus, a leading QCA application from Sanders Data Systems, with an eCRF within ICON Medical Imaging's proprietary Medical Image Review and Analysis (MIRA(TM)) system. The integration of QCAPlus adds to the existing visualisation, analysis and project management applications currently available through MIRA(TM).
"Clinical trials incorporating QCA have made a significant impact in cardiovascular drug and device development," commented Jonathan Goldman MD, Chief Medical Officer, ICON Medical Imaging. "Building QCA capabilities into MIRA(TM) represents the latest in a series of innovations designed to boost the integrity and reproducibility of clinical trial data, and enhances our leadership in the field of imaging within clinical research."
Coronary angiography is the gold standard for the diagnosis of
obstructive coronary artery disease. The use of quantitative analysis for
angiographic interpretation in clinical studies reduces variability and
enables findings to be statistically categorised, leading to more reliable
study results. The complexity of capturing angiographic analyses in a
clinical trials database inspired the integration of QCAPlus with ICON's
MIRA(TM) system. The new integrated system enables quantitative
measurements and qualitative interpretations to be captured in a single
electronic case report form i
|SOURCE ICON plc|
Copyright©2008 PR Newswire.
All rights reserved